Exosome-transmitted LINC00960 and LINC02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder cancer cells

CURRENT STATUS: POSTED

Cheng-Shuo Huang
Graduate Institute of Pathology and Parasitology, National Defense Medical Center

Jar-Yi Ho
Graduate Institute of Life Sciences, National Defense Medical Center

Jung-Hwa Chiang
Department of Pathology, Catholic Cardinal Tien Hospital

Cheng-Ping Yu
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center

Dah-Shyong Yu
Tri-Service General Hospital, National Defense Medical Center

yuds@ms21.hinet.net Corresponding Author

DOI:
10.21203/rs.3.rs-25015/v1

SUBJECT AREAS
Cancer Biology Oncology

KEYWORDS
Bladder cancer, exosome, epithelial-mesenchymal transition, long noncoding RNAs
Abstract

Background
Exosomes are essential for several tumor progression-related processes, including epithelial-mesenchymal transition (EMT). Long noncoding RNAs (lncRNAs) comprise a major group of exosomal components and regulate the neoplastic development of several cancer types; however, the progressive roles of exosomal lncRNAs in bladder cancer have rarely been addressed. In this study, we identified two potential aggressiveness-promoting exosomal lncRNAs, LINC00960 and LINC02470; we found that these lncRNAs potently induced EMT during bladder cancer progression.

Methods
Low-grade bladder cancer cells (TSGH-8301) were treated with conditioned media or exosomes derived from high-grade bladder cancer cells (T24 or J82), and the aggressiveness-promoting effects were evaluated. Cell viability, cell migratory/invasive activities and clonogenicity were compared to assess the response to these intercellular transmissions. Exosome-transmitted lncRNA candidates were screened with bioinformatic pipelines, and their expression levels were validated in bladder cancer cells and exosomes. Two novel lncRNAs, LINC00960 and LINC02470, were selected, and their roles and regulatory mechanisms in inducing the aggressiveness of bladder cancer cells were investigated.

Results
Exosomes derived from high-grade bladder cancer cells enhanced the viability, migration, invasion and clonogenicity of recipient low-grade bladder cancer cells and activated major EMT-upstream signaling pathways, including β-catenin signaling, Notch signaling, and Smad2/3 signaling pathways. Nevertheless, LINC00960 and LINC02470 were expressed at significantly higher levels in T24 and J82 cells and their secreted exosomes than in TSGH-8301 cells. Moreover, exosomes derived from LINC00960 knockdown or LINC02470 knockdown T24 cells significantly attenuated the ability of exosomes to promote cell aggressiveness and activate EMT-related signaling pathways in recipient TSGH-8301 cells.

Conclusion
Our findings indicate that exosome-transmitted LINC00960 and LINC02470 from high-grade bladder cancer cells promotes the malignant behaviors of recipient low-grade bladder cancer cells and
induces EMT by upregulating β-catenin signaling, Notch signaling, and Smad2/3 signaling. Both lncRNAs may serve as potential liquid biomarkers for the prognostic surveillance of bladder cancer progression.

**Background**
Bladder cancer is the seventh most prevalent cancer worldwide and the second most common urological malignancy behind prostate cancer. Its incidence is rising in most countries, with an estimated 549,393 new cases diagnosed in 2018 and 990,724 new cases expected in 2040 [1, 2]. In Taiwan, the incidence of bladder cancer is also increasing annually [3]. Bladder cancer exhibits a high frequency of relapse and a poor clinical outcome once the tumors progress to muscle invasion and drug resistance [4-8]. Therefore, it is imperative to clarify the underlying mechanisms of the critical progression of bladder cancer aggressiveness from low-grade to high-grade bladder cancer and frequent progression to muscle invasive disease.

During epithelial-to-mesenchymal transition (EMT), epithelial cells are converted to migratory and invasive cells [9]. Loss of E-cadherin expression has long been considered to be a leading hallmark of EMT, which leads to the loss of the typical polygonal, cobblestone morphology of epithelial cells. Alternatively, the cells acquire a spindle-shaped mesenchymal morphology and express markers that are associated with the mesenchymal cell state, notably neural cadherin (N-cadherin), vimentin and fibronectin [10]. The EMT program is triggered by the activation of several core transcription factors, including Snail, Slug, Zeb1/2, and Twist [11]. Recently, several reports have found that long noncoding RNAs (lncRNAs) play regulatory roles in tumor invasion and metastasis through EMT-based mechanisms in bladder cancer [12, 13].

Exosomes are membrane-derived vesicles containing proteins, double-stranded DNA, mRNA, miRNA, and lncRNA and participate in a variety of intercellular transmissions [14, 15]. Exosomes also promote the EMT program and may thereby play crucial roles in delivering oncogenic factors to regulate cell proliferation, motility and stress tolerance by functioning as intracellular mediators taken up by recipient cells [16-18]. Although many lncRNAs, such as LINC00152, LINC00355, LINC00958, and UCA1, have been reported to be closely related to the pathogenesis, progression, and
chemoresistance of bladder cancer [19-22], IncRNAs comprise a major group of exosomal components. However, the intercellular communication of exosome-transmitted IncRNAs during bladder cancer progression has rarely been addressed.

In this study, two potent candidate IncRNAs, LINC00960 and LINC02470, were screened out based on a series of selective criteria. After validation of their intracellular and exosomal expression levels, their biological effects and molecular regulation were evaluated, and the results indicated that exosome-transmitted LINC00960 and LINC02470 from high-grade bladder cancer cells aggravates low-grade bladder cancer cell malignant behaviors and promoted the EMT process.

Materials And Methods

Cell lines

Four human bladder cancer cell lines (low-grade, TSGH-8301 and TSGH-9202, and high-grade, T24 and J82; originally acquired from ATCC or Bioresource Collection and Research Center) were used in this study. All cells were incubated in RPMI 1640 medium containing 10% fetal bovine serum, 1 µg/ml penicillin and 1 µg/ml streptomycin (Life Sciences, Palo Alto, CA, USA) at 37 °C in a 5% CO₂ humidified incubator.

Isolation of exosomes from conditioned media

Exosomes were isolated by differential centrifugation of conditioned media collected from TSGH-8301, T24 and J82 cells. Cells were grown in medium containing 10% exosome-depleted FBS (SBI System Biosciences, Palo Alto, CA, USA). After removing cells and other debris by centrifugation at 3000 × g for 30 minutes, the supernatant was subsequently centrifuged at 10000 × g for 1 hour to remove shedding vesicles and other large vesicles. Finally, the supernatant was recentrifuged at 120000 × g for 3 hours at 4 °C. The exosome pellets were resuspended in PBS and stored at 4 °C before experimental analyses.

Nanoparticle tracking analysis

The number and size of exosomes were directly tracked using the NanoSight NS 300 system (NanoSight Technology, Malvern, UK). Exosomes were resuspended in PBS at a concentration of 5 µg/ml and further diluted 100-fold to achieve a concentration between 20 and 100 objects per frame. Samples were manually injected into the sample chamber at ambient temperature. Each
sample was detected in triplicate with a 488-nm laser and a high-sensitivity scientific complementary metal-oxide semiconductor camera at a camera setting of 13 with an acquisition time of 60 seconds and a detection threshold setting of 7. The detection threshold was similar in all the samples and was applied using NTA 3.0 analytical software.

Transmission electron microscopy
For conventional transmission electron microscopy, the exosome pellet was placed in a droplet of mixed buffer (1:1 of 2.5% glutaraldehyde (in 0.1 M sodium cacodylate, pH 7.4) and 4% paraformaldehyde (in 1 × PBS)) and fixed overnight at 4 °C. Samples were rinsed in PBS buffer (3 times, 10 minutes each) and further fixed in 1% osmium tetroxide (in double distilled water) for 50 minutes at room temperature. The samples were then embedded in 10% gelatin, fixed in glutaraldehyde at 4 °C, and cut into tiny blocks (< 1 mm³). The samples were dehydrated with an alcohol gradient (70%, 90%, 95%, and 100%) for 10 minutes at each step. Pure alcohol was then exchanged with propylene oxide, and specimens were embedded in increasing concentrations (25%, 50%, 75% and 100%) of Quetol-812 epoxy resin mixed with propylene oxide for a minimum of 2 hours per step. Samples were embedded in pure, fresh Quetol-812 epoxy resin and polymerized at 70 °C for 24 hours. Ultrathin sections (300 nm) were cut using a Leica UC6 ultramicrotome. After staining with uranyl acetate for 10 minutes and lead citrate for 5 minutes at room temperature, exosome morphology was observed by transmission electron microscopy (Hitachi, HT7700, Japan) under operation at 120 kV and adjusted to the appropriate zoom.

Dynamic uptake of exosomes
Isolated exosomes were labeled with FITC-conjugated CD9 antibody (CD9-FITC-labeled exosomes). TSGH-8301 cells were pretreated with Hoechst DNA counterstain (Sigma-Aldrich, San Jose, CA, USA) for 24 hours. Subsequently, cells were treated with CD9-FITC-labeled exosomes in serum-free medium. Treated cells were photographed for their entirety using the phase-contrast status at low power assessment every 30 minutes, and spontaneously fluorescent images were photographed with the Hoechst DNA channel (360 nm/460 nm excitation/emission) and FITC channel (400 nm/455 nm excitation/emission) using a Lionheart FX Automated Microscope. The dynamic uptake of exosomes
was recorded using a BioTek Lionheart FX microscope (BioTek, Winooski, VT, USA). All experiments were performed in triplicate.

**Cell viability assay**
The viability of the bladder cancer cells was determined using the 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide (MTT, Sigma-Aldrich) assay. Cells were seeded in 96-well plates at 5000 cells/well and cultured overnight. After treatment with the indicated concentrations of conditioned media or exosomes for 48 hours, cells were incubated with 0.1 mg/ml MTT for 3 hours, and formazan was dissolved in dimethyl sulfoxide (Sigma-Aldrich) at room temperature for 10 minutes. The absorbance at 560 nm was measured with a spectrophotometer (Bio-Rad Inc, Hercules, CA, USA). All experiments were performed in triplicate.

**Cell migration and invasion assay**
In wound healing assays, $1 \times 10^5$ cells were seeded in 6-well plates and incubated to 90% confluence before transfection. After treatment with the indicated concentrations of conditioned media or exosomes for 24 hours, cells were scraped with a sterile 200 µl pipette tip to generate a clear line in the wells at time 0. The migrated cells were observed with a phase-contrast microscope every 8 hours (Leica DMI4000B, Bucks, UK), and the wound width at the designated time was measured with ImageJ software. All experiments were performed in triplicate.

Transwell migration assays were performed using 8 µm Transwell chambers (Corning, Steuben County, NY, USA) with $1 \times 10^4$ cells for each exosome treatment. Transwell invasion assays were evaluated with the same chambers-coated with 1 mg/ml Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) with $2 \times 10^4$ cells for each exosome treatment. The migration and invasion chambers were incubated in a humidified 5% CO$_2$ incubator at 37 °C for 24 hours. Cells were then fixed with 4% paraformaldehyde, and the inner surface of the upper chambers was wiped with cotton swabs to remove unmigrated or uninvaded cells. After washing, the chambers were stained with crystal violet (Sigma-Aldrich) for 15 minutes, and the Transwell membranes were torn and kept in slides. Five random fields of each treatment were photographed at 100 × magnification, and the crystal violet-stained area was calculated using ImageJ software. Each condition was plated in triplicate.
Colony formation assays
Exosome effects on clonogenicity were evaluated with a colony-formation assay. In brief, 0.5 ml of 0.5% agarose in complete medium was used as the bottom agar in a 12-well plate, and $2 \times 10^4$ cells were mixed with 0.3% agarose in complete medium at 48 hours after treatment with the indicated concentrations of exosomes. Cells were maintained in a humidified 5% CO$_2$ incubator at 37 °C for 21 days with fresh medium replacement every three days. Cell colonies were stained with crystal violet (Sigma-Aldrich) for 1 minute and destained with tap water for 15 minutes. Colonies were counted using ImageJ software for each well, and triplicate repeats were performed for each condition.

Western blotting
Total protein was extracted from cultured cells and exosomes using RIPA lysis and extraction buffer (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with a protease inhibitor cocktail (Roche, Basel, Switzerland) at a ratio of 100:1. The protein concentration was determined by a BCA protein assay kit (Thermo Fisher Scientific, Waltham, USA). Thirty micrograms of protein was subjected to 10% SDS-PAGE and then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Burlington, MA, USA). The membrane was blocked with 5% nonfat milk in TBST buffer and incubated with primary antibodies against CD9, CD63, beta-catenin, TCF4, Notch1, Notch4, HES1, Smad2/3, p-Smad2/3, Slug, Snail, Twist, Zeb2, E-cadherin, N-cadherin, vimentin, MMP2, MMP9 or GAPDH (Abcam, Cambridge, UK and Cell Signaling Technology, Danvers, MA, USA) overnight at 4 °C. Subsequently, the blots were washed with TBST, followed by incubation with HRP-conjugated goat anti-mouse or goat anti-rabbit secondary antibody (1:5000; Santa Cruz Biotechnology, Dallas, TX, USA) at room temperature for 1 hour. The immunoreactive bands were visualized with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Burlington, MA, USA) and analyzed with the UVP GelStudio PLUS System (Analytik Jena AG, Thuringia, Germany). Each condition was performed in triplicate.

RT-qPCR assay
Total RNA was extracted from cultured cells and exosomes using TOOLSmart RNA Extractor (BIOTOOLS, Taiwan (R.O.C.)). The concentration of total RNA was evaluated using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Total RNA was reverse transcribed into cDNA using the
ToolsQuant II Fast RT Kit with Oligo (dT) primer (BIOTOOLS) in a 20 µL reaction system consisting of 1000 ng template, 2 µL of 10 x RT Reaction Premix with Oligo (dT) primer, 1.5 µL of ToolsQuant II Fast RT and RNase-free ddH₂O. The mixture was centrifuged briefly and incubated with reverse transcription at 42 °C for 15 minutes, followed by enzyme inactivation at 85 °C for 5 minutes.

Quantitative real-time PCR was performed in a 20 µL reaction system containing 3 µL of diluted cDNA, 10 µL of TOOLS 2X SYBR qPCR Mix (BIOTOOLS), 0.5 µL of gene-specific forward and reverse primers (10 pmol/µL) and 6.5 µL RNase-free ddH₂O on a QuantStudio 5 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Supplementary Table 1 lists the primer sequences used in this study. Briefly, after an initial denaturation step at 95 °C for 15 minutes, amplifications were carried out with 45 cycles at a melting temperature of 95 °C for 15 seconds, an annealing temperature of 60 °C for 20 seconds and elongation temperature of 72 °C for 20 seconds. The specificity of amplicons was confirmed by melting curve analysis. GAPDH was used as a reference gene. The relative expression levels of target genes were calculated using the 2−ΔΔCT method. All experiments were conducted in triplicate, and no-template controls were included in each run.

Knockdown of LINC00960 and LINC02470

The LINC00960 and LINC02470 siRNAs and their negative control (NC) siRNAs were purchased from Dharmacon (GE Healthcare Dharmacon, Lafayette, CO, USA). T24 cells were transfected with 40 nM siRNA oligos or NC using Lipofectamine 2000 reagents (Invitrogen) according to the manufacturer’s instructions. The cells were harvested for RNA extraction, protein extraction or functional assays after 48 hours of transfection of each siRNA, and RT-qPCR was used to determine the transfection efficiency. The data were analyzed with CELL Quest software. Each experiment was conducted in triplicate.

Statistical analysis

All statistical analyses were performed with SPSS 17.0 (IBM, SPSS, Chicago, IL, USA) and GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA). Data were recorded as continuous variants and analyzed with Student’s t test. The results are expressed as the mean ± standard deviation of at least
three separate experiments. All statistical tests and \( p \) values were two-sided, and the level of significance was set to \(< 0.05 (*)\), \(< 0.01 (**)\), or \(< 0.001 (***)\).

**Results**

Conditioned media of high-grade bladder cancer cells increased the cell viability and motility of recipient low-grade bladder cancer cells

To evaluate the regulatory effects of conditioned medium (ConMed) from different cells, cell viability and motility were compared after three days of treatment with each ConMed. Four groups were treated with TSGH-8301-ConMed, T24-ConMed, or J82-ConMed in a series of volumes (0, 20, 40, 60, 80, 100 \( \mu l \)), and the PBS control served as the comparison baseline. TSGH-8301 cells treated with any ConMed revealed a slower growth rate than that of the PBS control, which implied that each ConMed contained debris and metabolites and decreased the cell growth rate. However, each ConMed markedly increased the growth rate in a dose-dependent manner (Fig. 1A). Moreover, compared to the PBS control, T24-ConMed also increased the migratory ability in the wound healing assay (Fig. 1B and 1C). These results suggest that some component(s) in the conditioned media of higher-grade bladder cancer cells possess the ability to promote the migration of TSGH-8301 cells and that exosomes transmission should be competent for intercellular communication.

**Qualitative and quantitative detection of exosomes**

Bladder cancer cell-derived exosomes were isolated by the ultracentrifuge method from the conditioned media of TSGH-8301, T24 and J82 cells. NTA and TEM showed that the mean size and concentration of exosomes (Exos) were as follows: TSGH8301-Exos: mean size 116.8 \( \pm \) 3.0 nm and concentration \( 3.68 \times 10^{10} \) particles/ml; T24-Exos: mean size 118.5 \( \pm \) 0.8 nm and concentration \( 1.15 \times 10^{11} \) particles/ml; and J82-Exos: mean size 124.2 \( \pm \) 1.0 nm and concentration \( 4.36 \times 10^{10} \) particles/ml (Fig. 1D and 1E). Western blotting revealed that the exosomal surface markers CD9 and CD63 [23] were present on exosomes derived from each cell line (Fig. 1F).

**Exosomes serve as mediators of intercellular communication**

After cotreatment of TSGH-8301 cells with Hoechst DNA counterstain and CD9-FITC-labeled exosomes for 24 hours, the staining intensity of the CD9-FITC-labeled exosomes was markedly increased (Fig. 2A) in a time-dependent manner; staining tended to become saturated before 6 hours (Fig. 2B).
T24-Exos and J82-Exos promote the malignant behavior of recipient TSGH-8301 cells

To evaluate the biological effects of T24-Exos and J82-Exos on regulating cell viability, migration and invasion of TSGH-8301 cells, recipient TSGH-8301 cells were treated with increasing concentrations of TSGH-8301-Exos, T24-Exos, or J82-Exos (0, 20, 40, 60, 80, 100, 120 and 140 µg/ml) and PBS control for 48 hours. Compared to the control, T24-Exos and J82-Exos significantly increased the cell viability of TSGH-8301 cells in a concentration-dependent manner, but the inductive effect reached a plateau pattern when the concentration of exosomes was higher than 40 µg/ml (Fig. 3A). Then, the time-dependent effects on cell viability were evaluated with 40 µg/ml of each exosome. T24-Exos and J82-Exos significantly promoted the cell viability of TSGH-8301 cells, especially J82-Exos, which demonstrated more potent promotive effects after 24 hours of treatment (Fig. 3B). Furthermore, T24-Exos and J82-Exos also significantly promoted the migratory (Fig. 3C, 3D, 3E, and 3H) and invasive (Fig. 3F and 3I), clonogenicity (Fig. 3G and 3J) abilities of TSGH-8301 cells. Thus, after exposure to T24-Exos and J82-Exos, higher cell viability and motility were observed in recipient TSGH-8301 cells in dose- and time-dependent patterns.

The expression of epithelial-mesenchymal transition-associated molecules was promoted after exosome treatment

Since T24-Exos and J82-Exos exerted higher inductive effects on cell motility than cell viability, which indicated that T24-Exos and J82-Exos participated in some signaling pathways that obviously induced cell migration and moderately increased cell proliferation. Therefore, the EMT process seemed to be a potential candidate for further analyses. TSGH-8301 cells were separately treated with PBS control, TSGH-8301-Exos (40 µg/ml), T24-Exos (40 µg/ml), and J82-Exos (40 µg/ml) for 3 days, and treated cells were harvested for western blotting. In Fig. 4, EMT transcription factors (EMT-TF) were first compared, and Snail, Slug and Zeb2 were significantly upregulated after T24-Exos or J82-Exos treatment, while Twist was significantly upregulated after T24-Exos treatment compared to PBS control treatment. Subsequently, markers of epithelial-like or mesenchymal-like properties were
compared, and the epithelial marker E-cadherin was significantly reduced after T24-Exos or J82-Exos treatment, although it was also slightly reduced after TSGH-8301-Exos treatment. Conversely, the mesenchymal marker N-cadherin and the interstitial indicator vimentin were increased after T24-Exos or J82-Exos treatment. Moreover, matrix metalloproteases were analyzed to infer the invasive potential, and MMP2 and MMP9 were significantly increased after T24-Exos or J82-Exos treatment. In short, T24-Exos or J82-Exos induced EMT in recipient TSGH-8301 cells by upregulating most EMT-TFs and resulted in a decrease in E-cadherin but an increase in N-cadherin, vimentin, MMP2 and MMP9.

Second, three major upstream signaling cascades of the EMT process, including β-catenin/TCF4 signaling, Notch/HES1 signaling and TGF-β/SMAD signaling, were analyzed. As shown in Fig. 4, β-catenin was significantly upregulated after TSGH8301-Exos, T24-Exos or J82-Exos treatment compared to the PBS control group. However, TCF4 was upregulated after T24-Exos treatment but was not affected by J82-Exos or TSGH8301-Exos treatment. Then, T24-Exos or J82-Exos also induced Notch1, Notch4, and HES1 upregulation when compared to the PBS control group. In addition, T24-Exos or J82-Exos also induced the upregulation and phosphorylation/activation of Smad2/3. In contrast, TSGH-8301-Exos downregulated Smad2/3 and decreased their phosphorylation/activation. In summary, either T24-Exos or J82-Exos induced EMT in recipient TSGH-8301 cells, and three major upstream signaling cascades were also obviously activated after T24-Exos or J82-Exos treatment. These results implicated that there were some broad-spectrum regulators in the exosomes derived from high-grade bladder cancer cells, which led to comprehensive induction of the EMT process in recipient TSGH-8301 cells.

**Screening and validation of exosomal IncRNAs**

IncRNAs comprise a considerable proportion of exosomal components, and several IncRNAs have been reported to contribute to multiple oncogenic steps, including tumor formation, progression, and/or metastatic processes in many cancer types; hence, this study was designed to evaluate the potential of exosome-transmitted IncRNAs to induce aggressiveness by promoting the EMT process. Exosome-transmitted IncRNA candidates were screened with bioinformatic pipelines of the InCARe database (https://Incar.renlab.org/) by overlapping the top 200 differentially expressed IncRNAs
between normal and tumoral bladder tissues and those between low-grade and high-grade UCC. After screening, 17 potential candidates were intersected and subjected to RT-qPCR validation in bladder cancer cells and exosomes. Comparison of AATBC, LINC00958, LINC00960, SNHG18, MIR4697HG, MEG3, TRMU, IGFL2-AS1, LINC01451, GLIDR, LOC728673, LINC01637, LINC01291, LINC02740, XIST, KLF3-AS1, and SSTR5-AS1 expression was performed in TSGH-8301, TSGH-9202, T24 and J82 cells (Fig. 5A and 5B). Seven IncRNAs, including LINC00958, LINC00960, MIR4697HG, LINC01637, LINC01291, LINC02740, and XIST, had expression levels that were at least 2-fold higher in T24 and J82 cells than in TSGH-8301 cells. Their expression in exosomes was further compared. Only LINC00960 and LINC02470 were expressed in T24-Exos and J82-Exos at levels that were 2-fold higher than those in TSGH-8301-Exos (Fig. 5C). Therefore, subsequent analyses of the biological effects and molecular regulation of these two IncRNA candidates were performed. Intracellular LINC00960 and LINC02470 were obviously increased in recipient TSGH-8301 cells after T24-Exos or J82-Exos treatment, although the difference in LINC02470 expression did not reach statistical significance in the J82-Exos-treated group (Fig. 5D).

Exosomes derived from LINC00960 knockdown or LINC02470 knockdown T24 cells reduced aggressive behavior in recipient TSGH-8301 cells

To confirm the efficacy of LINC00960 and LINC02470 siRNA, intracellular and exosomal levels of LINC00960 and LINC02470 were compared among control siRNA-, siLINC00960- and siLINC02470-transfected T24 cells. As shown in Fig. 6A, siLINC00960 specifically and significantly reduced LINC00960 expression by more than 50%, and siLINC02470 specifically and significantly reduced LINC02470 expression by ~ 50% at both the intracellular levels and the exosomal level compared to that in the control siRNA groups. Moreover, the biological effects of exosomes derived from each siRNA transfectant were further assessed by detecting the cell viability, migration, invasion and clonogenicity of exosome-recipient TSGH-8301 cells. In Fig. 6B, compared to exosomes derived from control siRNA-transfected T24 cells, exosomes derived from siLINC00960-transfected T24 (T24 siLINC00960-Exos) or siLINC02470-transfected T24 (T24 siLINC02470-Exos) cells demonstrated significantly reduced inductive effects on cell viability (Fig. 6C), cell migration(Fig. 7A, 7B, 7C, and 7F)
and invasion (Fig. 7 d, and 7 fg) clonogenicity (Fig. 7E, and 7H) Therefore, the aggressiveness-promoting abilities of T24-Exos in recipient TSGH-8301 cells were significantly attenuated after knockdown of either LINC00960 or LINC02470. Exosomes derived from LINC00960 knockdown or LINC02470 knockdown T24 cells reduced the expression levels of EMT-associated molecules in recipient TSGH-8301 cells TSGH-8301 cells were separately treated with PBS control, TSGH8301-Exos (40 µg/ml), T24-Exos (40 µg/ml), T24 siLINC00960-Exos (40 µg/ml), and T24 siLINC02470-Exos (40 µg/ml) for 3 days, and treated cells were harvested for western blotting. In Fig. 8, EMT-TFs were compared, and Snail and Slug levels were significantly reduced after T24 siLINC00960-Exos or T24 siLINC02470-Exos treatment when compared to those in the T24-Exos-treated group. However, Twist and Zeb2 levels were similar among those three groups. In addition, N-cadherin, vimentin, MMP2 and MMP9 levels were also significantly reduced after T24 siLINC00960-Exos or T24 siLINC02470-Exos treatment when compared to those in the T24-Exos-treated group, although E-cadherin levels were similar among those groups. Moreover, three major upstream signaling cascades of the EMT process described in Fig. 4 were also analyzed. In Fig. 8, T24 siLINC00960-Exos or T24 siLINC02470-Exos significantly reduced β-catenin and TCF4 expression (β-catenin signaling), Notch1, Notch4 and HES1 expression (Notch signaling), and Smad2/3 expression and their phosphorylation/activation (Smad2/3 signaling) when compared to that in the T24-Exos-treated group. In summary, either T24 siLINC00960-Exos or T24 siLINC02470-Exos attenuated the T24-Exos-induced EMT process and its related regulatory mechanism in recipient TSGH-8301 cells. These results suggest that both LINC00960 and LINC02470 play comprehensive roles in EMT regulation and thereby promote the aggressiveness of recipient TSGH-8301 cells.

Discussion
Bladder cancer is usually multifocal with high recurrence and metastasis, and the EMT process has been comprehensively involved in bladder cancer progression [24, 25]. Nonmuscle invasive bladder cancer (NMIBC) accounts for more than 70% of newly diagnosed bladder cancers, and more than half of NMIBCs ultimately develop recurrence; approximately 15% of NMIBCs progress to muscle-invasive and/or metastatic diseases, which are highly connected with the EMT process [26, 27]. The
multifocality of bladder cancer has been hypothesized to originate from intraluminal monoclonal expansion (clonal) [28, 29] or spontaneous transformation of multiple cells by virulent environmental agents (field effect) [30]. It has been characterized by early genetic instability or aberrantly epigenetic methylation [31–33]. Our findings implicated that exosomes function as potential environmental agents as the “field effect” to promote bladder cancer progression, which might lead to higher severity of multifocal tumors or more malignant behaviors of NMIBC cells.

The key regulators of the EMT process are E-cadherin, N-cadherin, vimentin, Snail, Slug, Twist, and Zeb-2, and most of them have been correlated with bladder cancer progression via either genetic or epigenetic regulation [34]. Currently, little is known about the association between the epigenetic regulation of exosome-transmitted IncRNAs in the EMT process and bladder cancer progression. In this study, we found that exosomes derived from high-grade bladder cancer cells indeed promoted the viability, motility, and clonogenicity of low-grade bladder cancer cells via enhancement of the EMT process. Furthermore, we identified two novel exosomal IncRNAs, LINC00960 and LINC02470, that both play pivotal roles in the EMT process and promote the aggressiveness of bladder cancer cells (Fig. 9A).

Exosomes are key elements that can facilitate intercellular communication and modulate tumor cells by influencing major cellular processes such as apoptosis, cell differentiation, angiogenesis and metastasis [35]. Bladder cancer cells have been reported to undergo EMT transformation after exposure to muscle-invasive bladder cancer exosomes [36]. Exosomes have also been reported to enhance cancer progression and recurrence in hepatocellular carcinoma via the MAPK/ERK signaling pathway [37]. Our results showed that low-grade bladder cancer cells (TSGH-8301) treated with high-grade bladder cancer cell-derived exosomes (T24-Exos or J82-Exos) had an increase in mesenchymal proteins (N-cadherin and vimentin) and a decrease in E-cadherin. T24-Exos or J82-Exos also significantly promoted the migratory and invasive abilities of recipient TSGH-8301 cells. The morphology of the recipient cells gradually changed into spindle-shaped mesenchymal-like cells after T24-Exos or J82-Exos treatment (Supplementary Fig. 1). Comparatively, TSGH-8301-Exos treatment did not change their behaviors and morphology in an autocrine manner. This suggests that exosomes
derived from cells of different aggressiveness lead to different levels of aggressiveness-promoting effects in recipient bladder cancer cells.

The three most representative EMT upstream pathways, β-catenin/TCF signaling, Notch signaling and Smad2/3 signaling, were assessed to determine their involvement in exosome-induced EMT. Aberrant activation of β-catenin/TCF signaling is involved in a number of tumors, most notably colorectal carcinomas. TCF4 has been reported to transactivate Snail, Slug and Zeb1 and promote the EMT process [38, 39]. Notch1 signaling increases the DNA binding ability of NF-κB and thereby induces the expression of MMP9, which remodels the extracellular matrix and facilitates the extravasation of several cancer cells. Notch also stabilizes cytoplasmic β-catenin and activates other pathways, such as ERK and NF-κB, which induce the expression of Snail, Slug and LEF-1 transcription factors [40–42]. Smad complexes bind to regulatory elements and induce the transcription of key genes associated with EMT. Expression of activated Smad2 promotes mesenchymal spindle tumor cell invasion, which also regulates the expression of Snail, Slug and Twist to suppress the expression of E-cadherin [43–45]. Our results showed that β-catenin expression can be induced by treatment with each type of exosome, but its downstream transcription factors, especially TCF4, were significantly induced by T24-Exo treatment alone. The expression levels of Notch1, Notch4, Smad2 or Smad3 were all significantly upregulated by T24-Exos or J82-Exos treatment. T24-Exos or J82-Exos also induced the expression of the EMT-transcription factors Slug, Snail, Twist and Zeb2, which ultimately suppressed E-cadherin expression but promoted N-cadherin, vimentin, MMP2 and MMP9 expression in bladder cancer cells.

Several IncRNAs are involved in the EMT process and the degree of malignancy of tumors [46]. The main advantage of IncRNAs that make them suitable as cancer diagnostic and prognostic biomarkers is their high stability while circulating in body fluids, especially when they are encapsulated in exosomes or apoptotic bodies [47]. Several IncRNAs are associated with bladder cancer initiation and progression. LINC00958 has a regulatory role in bladder cancer progression, as its knockdown decreases cell viability, migration, and invasion [48]. LINC00355 is upregulated in bladder cancer samples and contributes to apoptosis inhibition, cell proliferation, and migration [49]. The urothelial
carcinoma-associated (UCA1) IncRNA is also involved in cell proliferation, migration, invasiveness, and drug resistance of bladder cancer cells [50]. LINC00152 is highly expressed in bladder cancer and confers its carcinogenic effects by activating the Wnt/β-catenin signaling pathway [51]. Cooperatively, exosomes and their contained IncRNAs are regarded as components of cell signal transmission that modulate endogenous cellular microenvironments because exosomes are able to relocate functional IncRNAs between cells [52]. In this study, we identified two novel IncRNAs, LINC00960 and LINC02470, that were highly expressed in high-grade bladder cancer cells and their cell-derived exosomes. To our knowledge, this is the first study to address the function of LINC00960 and LINC02470, not only in intracellular regulation of malignancy traits but also in intercellular communication, illustrating their driving force in influencing the behaviors of bladder cancer cells. Our data demonstrated that siLINC00960-Exos or siLINC02470-Exos derived from T24 cells significantly inhibited proliferation, migration, invasion, and colony formation in recipient cells compared with their parental T24 exosomes. In addition, T24 siLINC00960-Exos treatment significantly reduced the migratory capability of recipient cells compared to that with siLINC02470-Exos treatment, which implied that LINC00960 and LINC02470 regulates the EMT process via different routes. Moreover, we found that T24 siLINC00960-Exos or siLINC02470-Exos treatment obviously reduced β-catenin signaling, Notch signaling and Smad2/3 signaling; notably, the major EMT transcription factors, Snail and Slug, were significantly reduced, which led to the downregulation of N-cadherin and vimentin [53].

In summary, we demonstrated that high-grade bladder cancer cell-derived exosomes promoted the malignant traits of low-grade bladder cancer cells. T24-Exos or J82-Exos-transmitted LINC00960 and LINC02470 induced the aggressiveness of bladder cancer cells via autocrine or paracrine effects. In contrast, T24 siLINC00960-Exos or siLINC02470-Exos attenuated these aggressive-promoting effects and inhibited the EMT process. Thus, T24-Exos or J82-Exos-transmitted LINC00960 and LINC02470 could be important aggressiveness-promoting factors in bladder cancer progression (Fig. 9B). And it also implicated that intercellular epigenetic regulations play critical roles during bladder cancer progression.
Conclusions
Our findings indicate that exosome-transmitted LINC00960 and LINC02470 derived from high-grade bladder cancer cells promote the aggressive behavior of low-grade bladder cancer cells through intercellular communication and promote EMT by promoting β-catenin signaling, Notch signaling and Smad2/3 signaling. Both lincRNAs may serve as potential liquid biomarkers for the prognostic surveillance of bladder cancer patients in the future.

Abbreviations
ConMed
Conditioned medium
E-cad
E-cadherin
EMT
Epithelial-mesenchymal transition
Exos
Exosome
FBS
Fetal bovine serum
FITC
V-fluorescein isothiocyanate
GAPDH
Glyceraldehyde-3-phosphate dehydrogenase
HES1
Hes Family BHLH Transcription Factor 1
lncRNA
Long noncoding RNAs
lincRNA
Long intergenic non-coding RNA
N-cad
N-cadherin
NMIBC
Nonmuscle invasive bladder cancer
NTA
Nanoparticle tracking analysis
MIBC
Muscle invasive bladder cancer
MMPs
Matrix metalloproteinases
OD
Optical density
PBS
phosphate buffer saline
RPMI
Roswell Park Memorial Institute
RT-qPCR
Reverse transcription quantitative polymerase chain reaction
TCF-4
Transcription factor 4
TSGH
Tri-Service General Hospital
ZEB2
Zinc finger E-box binding homeobox 2

Declarations

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Availability of data and materials
Not applicable

Competing interests
The authors declare no competing interests.

Funding
This research was supported by grants the Tri-Service General Hospital (TSGH-D109-066), National Defense Medical Center (MAB-108-033), Cheng Hsin General Hospital (CH-NDMC-108-24 and CH-NDMC-109-06) and Cardinal Tien Hospital (CTH-101-1-2A18, CTH-102-1-2C03, and CTH-103-1-2C02).
Authors' contributions

C.S.H., J.Y.H. and D.S.Y. designed the research plan. C.S.H., J.Y.H., J.H.C., C.P.Y. and D.S.Y. conducted all experiments. C.S.H., J.Y.H., C.P.Y. and D.S.Y. drafted and edited the manuscript. J.Y.H. and DSY revised the manuscript.

Acknowledgements

We are grateful to the Medical Research Office of the Tri-Service General Hospital for their support in instrument use. We appreciate the technical assistance of the staff of the Instrument Center at the National Defense Medical Center.

Authors' information (optional)

Not applicable

References

1. Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8:1129.

2. Cancer tomorrow; WHO

Global cancer observatory

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer tomorrow; WHO: Geneva, Switzerland, 2018.

3. Health promotion administration ministry of health and welfare in Taiwan. Cancer Registry Annual Report. 2016 Taiwan. December 2018.

4. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol. 2009;56:430–42.

5. Babjuk M. Bladder Cancer in the Elderly. Eur Urol. 2018;73(1):51–2.

6. Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder
cancer. BJU Int. 2017;119(3):371–80.

7. Mari A, Campi R, Tellini R, Gandaglia G, Albisinni S, Abufaraj M, et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World. J Urol Springer Berlin Heidelberg. 2018;36:157–70.

8. Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69:438–47.

9. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol. 2011;27:347–76.

10. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–8.

11. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.

12. Mitra R, Chen X, Greenawalt EJ, Maulik U, Jiang W, Zhao Z, Eischen CM. Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun. 2017;8(1):1604.

13. Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Wu J, Huang G, Huang Y, Luo J, Liu X, Liu B, Chen X, Du Y, Chen R. Z. Fan, Mesenchymal Stem Cells Promote Hepatocarcinogenesis via IncRNA-MUF Interaction with ANXA2 and miR-34a. Cancer research. 2017;77(23):6704–16.

14. Mathivanan S, Ji H. Richard J. Simpson.Exosomes: Extracellular organelles important in intercellular communication. Journal of Proteomics. 2010, Pages 1907-1920.

15. Janusz Rak. Extracellular Vesicles – Biomarkers and Effectors of the Cellular Interactome in Cancer. Front Pharmacol. 2013;4:21.

16. Corrado C, Raimondo S, Chiesi A, Ciccia F, De Leo G, Alessandro R. Exosomes as
intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci. 2013 Mar 6;14(3):5338-66.

17. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol. 2011 Sep;33(5):441-54.

18. Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108:2419-25.

19. Tang XL, Zhou H, Li Y, Dai JY, Xian P, Song YP, Yuan F, Liu N. Higher expression of Linc00152 promotes bladder cancer proliferation and metastasis by activating the Wnt/β-Catenin signaling pathway. Med Sci Monit. 2019;25:3221-30.

20. Wieczorek E, Reszka E, mRNA. microRNA and IncRNA as novel bladder tumor markers. Clin Chim Acta. 2018;477:141-53.

21. Seitz AK, Christensen LL, Christensen E, et al. Profiling of long noncoding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Sci Rep. 2017;7:395.

22. Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo. Influencing Cell Growth Promoting Invasion FEBS letters. 2008;582:1919-27.

23. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010 Jun 4;285(23):17442-52.

24. McConkey DJ(), Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec;28(3-4)(1):335-44.
25. Garg. M(1). Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer. Cancer Metastasis Rev. 2015 Dec;34(4):691–701.

26. Fujii Y(1). Prediction models for progression of non-muscle-invasive bladder cancer: A review. Int J Urol. 2018 Mar;25(3):212–8.

27. Garg M1), Singh R(2). Epithelial-to-mesenchymal transition: Event and core associates in bladder cancer. Front Biosci (Elite Ed). 2019 Jun 1;11:150–165.

28. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med. 1992 Mar 12;326(11):737 – 40.

29. Simon R, Eltze E, Schäfer KL, Bürger H, Semjonow A, Hertle L, Dockhorn-Dworniczak B, Terpe HJ, Böcker W. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. 2001 Jan 1;61(1):355 – 62.]

30. Czerniak B, Dinney C, McConkey D. Origins of bladder cancer. Annu Rev Pathol. 2016 May 23;11:149–74.

31. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Primers. 2017 Apr;13:3:17022.

32. Acar Ö, Öz Kurt E, Demir G, Saraç H, Alkan C, Esen T, Somel M, Lack NA. Determining the origin of synchronous multifocal bladder cancer by exome sequencing. BMC Cancer. 2015 Nov;9:15:871.

33. Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 Feb;19(8):2241–56. 26(.
34. Lobo SM Monteiro-Reis, J, Henrique R. Carmen Jerónimo. Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer. Int J Urol. 2018 Mar;25(3):212–8.

35. Joana Maia S, Caja MC Carolina S, Moraes N, Couto. Bruno Costa-Silva. Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. Front Cell Dev Biol. 2018;6:18.

36. Franzen CA, Blackwell RH, Todorovic V, Greco KA, Foreman KE, Flanigan RC, Kuo PC, Gupta GN. Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes. Oncogenesis. 2015 Aug 17;4:e163.

37. Chen L, Guo P, He Y, Chen Z, Chen L, Luo Y, Qi L, Liu Y, Wu Q, Cui Y, Fang F, Zhang X, Song T, Guo H. HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway. Cell Death Dis. 2018 May 1;9(5):513.

38. Medici D1), Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell. 2008 Nov;19(11):4875–87.

39. Spaderna S 1), Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T, Brabletz T. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006 Sep;131(3):830–40.

40. Mohamed OA, Clarke HJ, Dufort D. Beta-catenin signaling marks the prospective site of primitive streak formation in the mouse embryo. Dev Dyn. 2004 Oct;231(2):416–24.

41. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol. 2002 Jul;4(7):487–94.
42. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007 Nov;213(2):374–83.

43. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem. 2008 Nov 28;283(48):33437–46.

44. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem. 2008 Nov 28;283(48):33437–46.

45. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, Crystal RG, de Herreros AG, Moustakas A, Pettersson RF, Fuxe J. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009 Aug;11(8):943–50.

46. Bolha L, Ravnik-Glavač M, Glavač D. Long Noncoding RNAs as Biomarkers in Cancer. Dis Markers. 2017;2017:7243968.

47. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013 May;113(1):1–11.

48. Seitz AK, Christensen LL, Christensen E, et al. Profiling of long noncoding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Sci Rep. 2017;7:395.

49. Wieczorek E, Reszka E, mRNA. microRNA and IncRNA as novel bladder tumor markers. Clin Chim Acta. 2018;477:141–53.

50. Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo. Influencing Cell Growth Promoting Invasion FEBS
letters. 2008;582:1919-27.

51. Tang XL, Zhou H, Li Y, Dai JY, Xian P, Song YP, Yuan F, Liu N. Higher expression of Linc00152 promotes bladder cancer proliferation and metastasis by activating the Wnt/b-Catenin signaling pathway. Med Sci Monit. 2019;25:3221–30.

52. TaftRJ PangKC, MercerTR, DingerM and Mattick JS. Non-coding RNAs: Regulators of disease. J Pathol. 2010;220:126–39.

53. Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014 Aug;2:33:62.

Figures
Figure 1
Conditioned medium of high-grade bladder cancer cells increased viability and motility of low-grade bladder cancer cells. (A) Cell viability was compared using MTT assays in TSGH-8301 cells treated with indicated conditioned medium, * p <0.05, ** p <0.01, *** p <0.001.

(B) The wound healing assay demonstrated that conditioned medium increased the migration of TSGH-8301 cells. Wound areas were measured at 0 hour, 8 hours, 16 hours, and 24 hours after scratching, and the representative images were showed at 0 hour and 24 hours after scratching. The wound closure distance was measured with the ImageJ software. The bars represent the mean and SD of three independent experiments, * p <0.05, ** p <0.01, *** p <0.001. (C) Nanoparticle tracking analysis was used to compare the average size of isolated exosomes. (D) Transmission electron microscopy was used to observe the morphology of isolated exosome. (E) Western blots revealed the presence of exosomal markers, CD9 and CD63, in isolated exosomes.
Figure 2

Exosomes serve as a mediator in intercellular communication. Bladder cancer cell derived exosomes were labeled with FITC-conjugated anti-CD9 antibody (Green) and counterstained with Hoechst 33342 (blue) for 24 hours, and exosomes uptake was observed under BioTek LIONheart FX microscope (A) for different spectra, and (B) merged figures were aligned upon a series of time.
Figure 3

T24-Exos and J82-Exos intensified aggressive behaviors of TSGH-8301 cells. (A) Cell viability
of different concentrations and (B) cell growth curve of different durations were compared using MMT assays in TSGH-8301 cells treated with each exosome, * p <0.05, ** p <0.01, *** p <0.001. (C, D) The wound healing assay demonstrated that T24 and J82 cells derived exosomes increased the migratory abilities of TSGH-8301 cells. Wound areas were photo-taken at 0 hour, 8 hours, 16 hours, 24 hours after scratching, and representative images were showed at 0 hour and 24 hours after scratching. The wound closure distance was calculated with the ImageJ software. The bars represent the mean and SD of three independent experiments, * p <0.05, ** p <0.01, *** p <0.001. (E, H) Transwell assay showed that T24 and J82 cells derived exosomes increased the migratory abilities of TSGH-8301 cells. (F, I) Matrigel-coated transwell assay showed that T24 and J82 cells derived exosomes increased the invasive abilities of TSGH-8301 cells. Representative images of the migrated and invaded cells were photo-taken at 24 hours and 72 hours after cell inoculation, respectively (G, J) Soft-agar colony formation assay was performed to examine the anchorage-independent survival of cells. The bar-charts showed the quantitative change of migration, invasion, and cell clones, respectively. All experiments were performed in at least triplicate, * p <0.05, ** p <0.01, *** p <0.001.
Exosomes mediated the expression of epithelial-mesenchymal transition related molecules. (A) Protein expression levels of EMT induced signaling molecules: β-catenin, TCF4, Notch1, Notch4, HES1, Smad2/3, and p-Smad2/3, and (B) EMT effectors: Snail, Slug, Twist, Zeb2, E-Cadherin, N-Cadherin, vimentin, MMP2, and MMP9 were compared after treatment with exosomes. The bar-charts showed the mean and SD of triplicate experiments. *, p <0.05, ** p <0.01, *** p <0.001.
Figure 5

Screening and validation of IncRNA candidates. (A) Schematic diagram of IncRNA screening.
Seventeen candidate IncRNAs were screened from intersection between top-200 IncRNA of Normal vs Tumor and Low-grade vs High-grade of bladder cancer datasets in the lnCAR database. (B) Intracellular expression levels of AATBC, LINC00958, LINC00960, SNHG18, MIR4697HG, MEG3, TRMU, IGFL2-AS1, LINC01451, GLIDR, LOC728673, LINC01637, LINC01291, LINC02740, XIST, KLF3-AS1, SSTR5-AS1 among different bladder cancer cells were compared using RT-qPCR. (C) Exosomal levels of LINC00958, LINC00960, MIR4697HG, LINC01637, LINC01291, LINC02740 and XIST were also compared using RT-qPCR. (D) Exosome-transmitted LINC00960 or LINC02470 transferred into TSGH-8301 was also evaluated by RT-qPCR. The bar-charts showed the mean and SD of triplicate experiments, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

**Figure 6**

Exosomes derived from LINC00960-knockdown or LINC02470-knockdown T24 cell conferred less aggressiveness-inductive abilities in recipient TSGH-8301 cells. LINC00960 or LINC02470 expression levels were compared by RT-qPCR in (A) cells and (B) exosomes. (C) Cell growth curve was compared using MTT assays in TSGH-8301 cell treated with each exosome. The quantitative results were shown as the bar-charts or growth curves for mean and SD of triplicate experiments, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. 

33
Figure 7

Exosomes derived from LINC00960-knockdown or LINC02470-knockdown T24 cell conferred
less aggressiveness-inductive abilities in recipient TSGH-8301 cells. T24 siLINC00960-Exos or T24 siLINC02470-Exos induced less migratory ability (A, B for wound healing assay and C, F for transwell assay), invasive ability (D, G for Matrigel-coated transwell assay), and clonogenicity (E, H for soft-agar colony formation assay) of recipient TSGH-8301 cell when compared to T24-Exos. All experiments were performed with identical time-points of Fig 3, and The bar-charts showed the mean and SD of triplicate experiments, * p <0.05, ** p <0.01, *** p <0.001.
Exosomes derived from LINC00960-knockdown or LINC02470-knockdown T24 cell reduced the expression levels of EMT related molecules in recipient TSGH-8301 cells. (A) Protein expression levels of EMT induced signaling molecules: β-catenin, TCF4, Notch1, Notch4, HES1, Smad2/3, p-Smad2/3, and (B) EMT effectors: Snail, Slug, Twist, Zeb2, E-Cadherin, N-Cadherin, vimentin, MMP2, and MMP9 were compared after treatment with each exosome. The bar-charts showed the mean and SD of triplicate experiments, * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 9

Schematic diagram of LINC00960 and LINC02470 based signaling circuit in low-grade bladder cancer. (a) Exosomes derived from LINC00960-knockdown or LINC02470-knockdown T24 cells reduce their malignancy driving force. (b) T24-Exos or J82-Exos transmitted LINC00960 and LINC02470 increased the expression of β-catenin signaling, Notch signaling, Smad2/3 signaling, transcription factors Snail, Slug, N-Cadherin, vimentin, MMP2, and MMP9, decreased E-Cadherin and promoted tumor progression of recipient TSGH-8301 cells.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

SupplementaryVideo4.mp4
SupplementaryVideo1.mp4
SupplementaryVideo3.mp4
Supplementary.docx
SupplementaryVideo2.mp4